[Arsenic and retinoic acid, towards targeted treatments of acute promyelocytic leukemia?].
Acute promyelocytic leukaemia is a key model system in cancer biology. Its exquisite sensitivity to retinoic acid constitutes the first example of differentiation therapy. The PML/RAR alpha fusion protein generated by the t(15; 17) translocation is the molecular basis of transformation. PML/RAR alpha induces transformation most likely through a dominant negative interference with the function of nuclear receptors leading to a differentiation block. The fusion protein also delocalizes PML and other nuclear body antigens and this alteration of nuclear protein traffic seems to play a role in growth control and apoptosis. The clinical response of this disease to retinoids and arsenic trioxide, both of which induce the degradation of the fusion protein, constitute the first example of a therapy directly targeted to a specific genetic lesion in a human cancer.
de Thé
H
H
CNRS UPR 9051, Hôpital St. Louis, Paris.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001151:Arsenic / Q000627:therapeutic use*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D014212:Tretinoin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014212:Tretinoin; D001151:Arsenic
Arsenic et acide rétinoïque, vers des traitements ciblés de la leucémie aiguë promyélocytaire?